Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
NCT03263091 · Kyntra Bio · PHASE3 · terminated · last registry update 2024-08-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study did not meet its primary efficacy endpoint.” | – | Registry record, Kyntra Bio |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGLN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-25Phase 3 first posted: Paul Potnuru, Vadadustat 900mg + Vadadustat 1200mg (NCT07086755)
- 2025-05-22Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT04313153)
- 2025-03-30Phase 3 first posted: Akebia Therapeutics, Erythropoiesis-Stimulating Agent (ESA) + Vadadustat (NCT06901505)
- 2025-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, vadadustat + placebo (NCT04478071)
- 2025-01-15Results posted on the registry: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
- 2025-01-13Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Roxadustat (NCT06772272)
- 2024-07-25Phase 3 first posted: USRC Kidney Research, Vadadustat + Erythropoiesis Stimulating Agent (NCT06520826)
- 2024-04-22Results posted on the registry: AstraZeneca, Roxadustat + rHuEPO (NCT04655027)
- 2024-03-27Also stopped (terminated): GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision